

Evidence dossier - Perceptive Advisors

GetCoattail manager profile: <https://getcoattail.com/manager/perceptive-advisors> | CIK 0001224962 | Rank #70 of 149 tracked managers by reported 13F value.

Background: Founded: 1999 | HQ: New York City, New York, US | Style: Healthcare and biotechnology focused investing across hedge fund, venture capital, private equity and private credit | Key person: Joseph Edelman

Background source: https://en.wikipedia.org/wiki/Perceptive_Advisors

1. Latest filing snapshot (as reported)

Period end: 2026-06-30 Filed: 2026-08-14 Reported total value: \$6.7B Positions: 109 Top-10 concentration: 47.3% of reported value.

Ticker	Company	Weight	Reported value
PRAX	Praxis Precision Medicines I	10.23%	\$682M
SYRE	Spyre Therapeutics Inc	5.76%	\$383M
CELC	Celcuity Inc	5.02%	\$334M
ASND	Ascendis Pharma A/S	4.66%	\$310M
RYTM	Rhythm Pharmaceuticals Inc	4.31%	\$287M
ROIV	Roivant Sciences Ltd	4.30%	\$286M
RLAY	Relay Therapeutics Inc	3.96%	\$264M
TVTX	Traverse Therapeutics Inc	3.20%	\$213M
KARD	Kardigan Inc	2.94%	\$196M
	Nuvalent Inc	2.93%	\$195M

2. Hypothetical 13F-clone results

WITHHELD for this manager. Price coverage of the disclosed portfolio is too low for a representative clone (latest-filing value coverage and the average unpriced segment weight are stated in section 4): a clone computed from the priced minority would misrepresent the disclosed portfolio. The filing snapshot above and the filing history below are complete as reported.

Method (summary): For each Form 13F filing in the history table, the clone takes the positions and weights exactly as disclosed (reported values at the period end). From the filing date until the next filing date, each position earns the return of its dividend-adjusted closing price (Yahoo Finance daily bars; split- and dividend-adjusted). At each new filing the clone rebalances to the newly disclosed weights. Positions that cannot be priced (non-U.S. listings, some recent IPOs and delisted names) are excluded from both the weights and the returns, and the covered share of reported value is stated in this dossier. The benchmark is SPY on the same dividend-adjusted basis over the identical window. Month-end values are used for drawdown and trailing-window statistics and are approximate.

3. Filing history - every clone input

Each row is one SEC Form 13F filing used by the clone. Accession numbers link to the filing index at sec.gov: <https://www.sec.gov/Archives/edgar/data/<CIK>/<accession without dashes>/<accession>-index.htm>

Quarter	Accession no.	Filed	CUSIPs
2016Q3	0001019056-16-001648	2016-11-14	186
2016Q4	0001019056-17-000309	2017-03-20	183
2017Q1	0001019056-17-000467	2017-05-15	166
2017Q2	0001012975-17-000624	2017-08-14	118
2017Q3	0001012975-17-000846	2017-11-14	129
2017Q4	0001012975-18-000171	2018-02-14	127

2018Q1	0001012975-18-000425	2018-05-15	126
2018Q2	0001012975-18-001030	2018-08-14	120
2018Q3	0001012975-18-001239	2018-11-14	112
2018Q4	0001012975-19-000177	2019-02-14	96
2019Q1	0001012975-19-000380	2019-05-16	95
2019Q2	0001012975-19-000583	2019-08-14	100
2019Q3	0001012975-19-000707	2019-11-14	103
2019Q4	0001012975-20-000250	2020-02-19	110
2020Q1	0001012975-20-000472	2020-05-18	109
2020Q2	0001012975-20-000701	2020-08-17	119
2020Q3	0001012975-20-000835	2020-11-16	119
2020Q4	0001012975-21-000086	2021-02-16	134
2021Q1	0001012975-21-000242	2021-06-10	133
2021Q2	0001012975-21-000326	2021-08-17	143
2021Q3	0001012975-21-000492	2021-12-03	133
2021Q4	0001012975-22-000081	2022-02-14	138
2022Q1	0001012975-22-000241	2022-05-16	131
2022Q2	0001012975-22-000365	2022-08-15	107
2022Q3	0001012975-22-000502	2022-11-14	113
2022Q4	0001012975-23-000099	2023-02-14	94
2023Q1	0001012975-23-000242	2023-05-16	98
2023Q2	0001012975-23-000365	2023-08-24	88
2023Q3	0001012975-23-000471	2023-11-14	87
2023Q4	0001012975-24-000112	2024-02-26	97
2024Q1	0001012975-24-000218	2024-05-15	105
2024Q2	0001012975-24-000346	2024-08-16	107
2024Q3	0001012975-24-000488	2024-11-14	102
2024Q4	0001012975-25-000090	2025-02-14	97
2025Q1	0001012975-25-000242	2025-05-15	86
2025Q2	0001012975-25-000446	2025-08-14	82
2025Q3	0001012975-25-000762	2025-11-14	90
2025Q4	0001012975-26-000155	2026-02-17	111
2026Q1	0001012975-26-000499	2026-05-29	91
2026Q2	0001012975-26-000777	2026-08-14	101

4. Coverage and adjustments

Price coverage at the latest filing: 80.6% of reported value is covered by our price history and included in the clone; the rest is excluded (mostly non-U.S. listings, recent IPOs, delisted names).

5. Disclaimer

This document and the associated web profile present a hypothetical replication ("13F clone") of the long U.S. equity positions disclosed on Form 13F. It is not the named fund's actual investment return: Form 13F excludes short positions, bonds, cash, non-U.S. listings, private holdings, leverage and fees, and positions are only observable quarterly, with a filing lag of up to 45 days. Nothing here is investment advice or a recommendation. Past hypothetical performance does not guarantee future results.